Keros Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Great. Good afternoon. I just have to read this disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So, I'm very pleased to introduce the CEO of Keros, Jas Seehra, and nice to see you Jas.
Thanks. Very pleased to be here today.
Great. Before we dive into granular questions, perhaps you can just provide a little bit of an overview on Keros and also your focus in the TGF beta superfamily.
Keros is a clinical-stage biopharmaceutical company focused entirely on the TGF-beta superfamily and inhibiting the signaling pathways of TGF-beta. We have three product candidates that are in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |